Advertisement

Neutralization of the Cytotoxic Effect of Anti-αGal Antibodies with Monoclonal Anti-idiotypic Antibodies

  • E. Koren
  • F. Milotic
  • F. A. Neethling
  • D. K. C. Cooper

Abstract

The use of the pig (or other widely divergent species) as a donor of organs for humans is dependent upon the development of a successful method of overcoming the hyperacute rejection (as well as any subsequent immune response) that is mounted in humans against grafted pig organs. The initiating factor in this hyperacute rejection is believed to be the presence of preformed antibodies in the recipient’s serum [1–4]. Recipient xenoreactive antibodies bind target molecules on the vascular endothelial cell surface of the xenografted organ and activate complement, leading to endothelial cell destruction and resulting in interstitial hemorrhage and edema.

Keywords

PK15 Cell Hyperacute Rejection Xenograft Rejection Normal Human Donor Serum Cytotoxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenberg, J.C., Hawkins, E., Rector, F. Mechanisms of immunological injury during antibody-mediated hyperacute rejection of renal heterografts. Transplantation, 1971; 11:151PubMedCrossRefGoogle Scholar
  2. 2.
    Hammer, C, Chaussey, C.H., Brendel, W. Preformed natural antibodies in animals and man. Outlook on xenotransplantation. Eur. Surg. Res., 1973; 5:162PubMedCrossRefGoogle Scholar
  3. 3.
    Paul, L.C. Mechanism of humoral xenograft rejection. In: Cooper, D.K.C., et al., (eds) Xenotransplantation. Springer, Heidelberg, 1991, p. 47Google Scholar
  4. 4.
    Piatt, J.L. Bach, F.H. Mechanism of tissue injury in hyperacute xenograft rejection. In: Cooper, D.K.C., et al., (eds) Xenotransplantation. Springer, Heidelberg, 1991, p. 69Google Scholar
  5. 5.
    Good, A.H., Cooper, D.K.C., Malcolm, A.J., et al. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xengrafting in humans. Transplant. Proc, 1992; 24:559PubMedGoogle Scholar
  6. 6.
    Cooper, D.K.C., Good, A.H., Koren, E., et al. Identification of a-galactosyl and other carbohydrates that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transplant. Immunol., 1993; 1:198CrossRefGoogle Scholar
  7. 7.
    Cooke, A. Regulation of the immune response. In: Roitt, L, et al. (eds) Immunology. Mosby-Year Book, Europe, Ltd., London, 1993, p. 94Google Scholar
  8. 8.
    Koren E, Milotic F, Neethling FA, Koscec M, Fei D, Kobayashi T, Taniguchi S, Cooper DKC. Murine monoclonal anti-idiotypic antibodies directed against human anti-αGal antibodies reduce in vitro and in vivo cytotoxicity of human and baboon sera to pig cells in culture: implications for pig-to-human organ xenotransplantation. Transplantation, 1996; 62:837PubMedCrossRefGoogle Scholar
  9. 9.
    Goding, J.W. Production of monoclonal antibodies. In: Goding, J.W. Monoclonal Antibodies: Principles and Practice. Academic Press, London, 1986, p.71Google Scholar
  10. 10.
    Koren, E., Kujundzic, M., Koscec, M., et al. Cytotoxic effects of human preformed anti-Gal IgG and complement on cultured pig cells. Transplant. Proc, 1994; 26:1336PubMedGoogle Scholar
  11. 11.
    Kujundzic, M., Koren, E., Neethling, F.A., et al. Variability of anti-αGal antibodies in human serum and their relation to serum cytotoxicity against pig cells. Xenotransplantation, 1994; 1:58CrossRefGoogle Scholar
  12. 12.
    Galili, U., Macher, B.A., Buehler, J., Shohet, S.B. Human natural anti-α-galactosyl IgG. II. The specific recognition of α(1–3)-linked galactose residues. J.Exp.Med., 1985; 162:573PubMedCrossRefGoogle Scholar
  13. 13.
    Miyajima, T., Higuchi, R., Kashiwabara, H., Yokoyama, T., Fujimoto, S. Anti-idiotypic antibodies in a patient with a functioning renal graft. Nature, 1980; 283:306PubMedCrossRefGoogle Scholar
  14. 14.
    Pohanka, E., Manfro, R.C., Oto, C, et al. Anti-idiotypic antibodies to HLA after donor-specific blood transfusion (DST). Transplant. Proc, 1989; 21:1806PubMedGoogle Scholar
  15. 15.
    Reed, E., Hardy, M., Benvenisty, A., et al. Effect of anti-idiotypic antibodies to HLA on graft survival in renal allograft recipients. New Engl. J. Med., 1987; 316:1450PubMedCrossRefGoogle Scholar
  16. 16.
    Rodey, G.A., Phelan, D.L. Association of anti-idiotypic antibody with successful second transplant of a kidney sharing HLA antigens with the previous hyperacutely rejected first kidney. Transplantation, 1989; 48:54PubMedCrossRefGoogle Scholar
  17. 17.
    Ye Y, Neethling, F.A., Niekrasz, M., et al. Intravenous administration of a-galactosyl carbohydrates reduces in vivo baboon serum cytotoxicity to pig kidney cells and transplanted pig hearts. Transplant. Proc, 1994; 26:1399PubMedGoogle Scholar
  18. Kobayashi, T., Taniguchi, S. Ye, Y et al. Prolongation of graft survival following pig-to-baboon heart transplantation by cobra venom factor (CVF) without natural antibody depletion. Submitted for publicationGoogle Scholar
  19. 19.
    Cooper, D.K.C., Ye, Y, Niekrasz N, , et al. Specific intravenous carbohydrate therapy - a new concept in inhibiting antibody-mediated rejection: experfience with ABO-incom-patible cardiac allografting in the baboon. Transplantation, 1993; 56:769PubMedCrossRefGoogle Scholar
  20. 20.
    Bannett, A.D., McAlack, R.F., Raja, R., et al. Experiences with known ABO-mismatched renal transplants. Transplant. Proc, 1987; 19:4543PubMedGoogle Scholar
  21. 21.
    Adair, J.R. Engineering antibodies for therapy. Immunol Rev., 1992; 130:5PubMedCrossRefGoogle Scholar
  22. 22.
    Jolliffe, L.K. Humanized antibodies: enhancing therapeutic utility through antibody engineering. Int. Rev. Immunol., 1993; 10:241PubMedCrossRefGoogle Scholar
  23. 23.
    Woodie, E.S., Thistlewaite, J.R., Jolliffe, L.K., et al. Humanized antibodies: successful transfer of immune modulating properties and idiotype expression. J. Immunol., 1992; 148:2756Google Scholar
  24. 24.
    Ghetie, V., Swindell, E., Uhr, J.W., Vitetta, E.S. Purification and properties of immuno-toxins containing one vs two deglycosylated ricin A chains. J. Immunol. Methods., 1993; 166:117PubMedCrossRefGoogle Scholar
  25. 25.
    Amlot, P.L., Stone, MJ., Cunningham, D., et al. A phase I study of an anti-CD22-degly-cosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood, 1993; 82:2624Google Scholar
  26. 26.
    Grossbard, M.L., Gribben, J.G., Freedman, A.S., et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin’s lymphoma. Blood, 1993; 81:2263Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • E. Koren
  • F. Milotic
  • F. A. Neethling
  • D. K. C. Cooper

There are no affiliations available

Personalised recommendations